The discovery of novel AKT inhibitor (4-(purin-6-yl)piperazin-1-yl)(benzofuran-2-yl)methanone for treatment of myeloid neoplasms: Computer modelling, synthesis and biological activity

Journal of Molecular Liquids 2026

View at publisher
Authors: Konstantin N. Semenov, Elena V. Pimenova, Vladislav A. Sokolov, Dina А. Senichkina, Natalia V. Petukhova, Maxim A. Gureev, Eugenia Y. Platonova, Dmitry S. Bug, Timofey Pyatyisbyancev, Alexander S. Zhuravlev, Olga S. Epifanovskaya, Ivan N. Gaponenko
+6 more Alena Igorevna Shakirova, Kirill Viktorovich Lepik, Yuri B. Porozov, Valeria A. Isakova, Ivan Moiseev, Vladimir V. Sharoyko
DOI: 10.1016/j.molliq.2026.129382
Cited by: 1
References: 61

Fields of Study & Subjects

PI3K/AKT/mTOR signaling in cancer Tuberous Sclerosis Complex Research Synthesis and biological activity

Publication details

Journal / source
Journal of Molecular Liquids
Publisher
Elsevier BV
Volume
449
Pages
129382–129382
Publication date
15 February 2026
Language
EN